Table 2. Clinicopathological features and mutation statuses of appendiceal mucinous tumours.

	Age/sex	Histology	Serosal exposure	Peritoneal implant	LN	MUC2a	MUC5ACa	GNAS	KRAS
1	30/M	LAMN	−	−	−	2+	−	—	c.35G>A
2	59/F	LAMN	−	−	−	2+	2+	c.602G>A	c.35G>A
3	72/M	LAMN	−	−	−	2+	−	—	c.34G>T
4	63/F	LAMN	−	−	−	2+	2+	c.601C>T	c.35G>T
5	62/F	LAMN	−	−	−	2+	−	—	—
6	53/M	LAMN	−	−	−	2+	1+	c.602G>A	c.38G>A
7	71/F	LAMN	−	−	−	2+	1+	—	c.35G>T
8	77/F	LAMN	−	−	−	2+	2+	c.602G>A	—
9	82/M	LAMN	−	−	−	2+	2+	c.602G>A	c.35G>A
10	72/M	LAMN	−	−	−	2+	1+	c.602G>A	c.35G>T
11	55/F	LAMN	−	−	−	2+	1+	—	c.38G>A
12	55/M	LAMN	−	−	−	2+	−	—	c.35G>A
13	72/M	LAMN	−	−	−	2+	−	—	c.35G>A
14	40/M	LAMN	−	−	−	2+	−	—	c.35G>A
15	84/F	LAMN	−	−	−	2+	2+	c.602G>A	c.35G>T
16	70/M	LAMN	−	−	−	2+	1+	—	c.35G>A
17	66/F	LAMN	+	−	−	2+	2+	—	c.35G>C
18	56/F	LAMN	+	+	−	2+	−	—	c.35G>A
19	52/F	LAMN	+	+	−	2+	2+	c.601C>T	c.35G>T
20	82/F	LAMN	+	+	−	2+	1+	—	c.38G>A
21	47/M	LAMN	+	+	−	2+	2+	—	c.35G>A
22	52/F	LAMN	+	+	−	2+	−	c.601C>T, c.602G>A	c.35G>A
23	59/M	LAMN	+	+	−	2+	2+	c.601C>T	c.35G>T
24	69/F	LAMN	+	+	−	2+	2+	—	c.35G>T
25	51/F	LAMN	+	+	−	2+	1+	—	c.35G>T
26	49/F	LAMN	+	+	−	2+	1+	—	c.35G>T
27	69/F	LAMN	+	+	−	2+	2+	c.602G>A	c.35G>T
28	64/F	LAMN	+	+	−	2+	2+	c.601C>T, c.602G>A	c.38G>A
29	56/M	LAMNb	N/A	+	−	2+	2+	c.601C>T	c.35G>A
30	57/F	LAMNb	N/A	+	−	2+	2+	c.601C>T	c.35G>A
31	67/F	LAMNb	N/A	+	−	2+	2+	c.601C>A	c.35G>A
32	68/M	LAMNb	N/A	+	−	2+	2+	c.601C>T	c.35G>T
33	58/F	MAC	+	−	−	2+	1+	—	c.34G>A
34	57/M	MAC	+	−	+	2+	1+	—	c.35G>A
35	51/M	MAC	+	+	+	−	1+	—	c.35G>A

Abbreviations: LN=lymph node metastasis; M=male; F=female; LAMN=low-grade appendiceal mucinous neoplasm; MAC=mucinous adenocarcinoma; N/A=not assessed.

^aThe immunohistochemistry for MUC2 and MUC5AC were scored as: 0, <10% positive cells; +1, 11–50% positive cells; +2, >50% positive cells.

^bTumour specimens of primary appendiceal tumours were unavailable and thus peritoneal (cases 29–31) or omental (case 32) deposits were analysed.